Mizuho raised the firm’s price target on Staar Surgical (STAA) to $18 from $17 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical appoints Deborah Andrews as CFO
- Staar Surgical Appoints Deborah Andrews as CFO
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed
- Staar Surgical Holds Annual Shareholders Meeting
- Cautious Optimism for Staar Surgical Amidst Uncertain Macroeconomic Recovery and Market Shifts